Currently leading computational strategies to develop non-invasive diagnostics for endometriosis at EndoGene.Bio.
- Current Focus: Developing clinically-relevant diagnostic models using whole genome methylation and transcriptomics data.
- Expertise: Specialist in patient stratification and disease progression prediction using large-scale genomic datasets.
- Background: PhD in Cancer Sciences from The University of Manchester with a focus on genomic risk prediction.
- Research History: Previous roles at Klinikum rechts der Isar (TUM), Wellcome Trust Sanger Institute, and the University of Oxford.
💻 Programming & Scripting
☁️ Workflow & Infrastructure
🔬 Bioinformatics & Multi-Omics
Bulk & scRNA-seq Whole Genome Methylation GWAS Polygenic Risk Scores (PRS) In Silico Drug Screening Biomarker Discovery Patient Stratification
📈 Analytics & Machine Learning
Machine Learning Models Drug Efficacy Prediction Regression Analysis Dimensionality Reduction (PCA/UMAP) Time-to-Event Modeling
- EndoGene.Bio: Leading the development of a novel, non-invasive diagnostic for endometriosis.
- Sanger Institute: Validated single-cell transcriptomics of menstrual fluid as a source for non-invasive diagnosis of endometrial pathologies.
- Oxford/Bayer Partnership: Identified and validated drug targets and biomarkers for endometriosis.
- Endometrial Cancer: Developed and validated a novel PRS using Manchester, UK Biobank and ECAC data.
- Neurological Disorders: Performed GWAS and meta-analyses for multiple sclerosis using large-scale biobank data (IMSGC, MultipleMS).
- Tiniakou et al., 2026: Whole genome methylation profiling of menstrual stem cells identifies novel biomarkers for endometriosis (Commun Med).
- Pérez-Moraga et al., 2025: Beyond one-size-fits-all: single-cell transcriptomic signatures predict drug efficacy and reveal responder subgroups in endometriosis (bioRxiv).
- Bafligil et al., 2022: Development and evaluation of polygenic risk scores for prediction of endometrial cancer risk in European women (Genet Med).
- Tapmeier et al., 2021: Neuropeptide S receptor 1 is a nonhormonal treatment target in endometriosis (Sci Transl Med).
👉 View my full publication list here
📍 Munich, Germany
💬 Native Cypriot Turkish | English (C2) | German (B1)